Cholecystokinin-8 vs BI 456906
Head-to-head comparison of Cholecystokinin-8 (Cholecystokinin (sulfated C-terminal octapeptide, CCK-8)) and BI 456906 (BI 456906, glucagon-like peptide-1/glucagon receptor dual agonist) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Cholecystokinin-8 | BI 456906 |
|---|---|---|
| Category | Endocrine Peptides | Weight Management |
| Full Name | Cholecystokinin (sulfated C-terminal octapeptide, CCK-8) | BI 456906, glucagon-like peptide-1/glucagon receptor dual agonist |
| Molecular Weight | 1143.2 Da | N/A |
| Half-Life | 1-2 min | Approximately 1 week |
| Amino Acids | DY(SO3H)MGWMDF-NH2 | N/A |
| Typical Dose | physiologic low-picomolar-nanomolar range|research-dependent | Trial-dependent; weekly SC dosing |
| Route | endogenous secretion|research IV/SC | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 97 | 10 |
| Research Status | Endogenous | Clinical |
Cholecystokinin-8 Benefits
- ✓gallbladder contraction
- ✓pancreatic enzyme release
- ✓satiety signaling
BI 456906 Benefits
- ✓weight reduction
- ✓improved glucose control
- ✓lower liver-fat burden
- ✓enhanced satiety
Cholecystokinin-8 Dosing
physiologic secretion|research-dependent
BI 456906 Dosing
once-weekly subcutaneous injection|stepwise titration|ongoing maintenance phase
Cholecystokinin-8 Side Effects
- ⚠abdominal cramping
- ⚠nausea
- ⚠biliary contraction
BI 456906 Side Effects
- ⚠nausea
- ⚠abdominal discomfort
- ⚠diarrhea
Research Overview
Cholecystokinin-8
CCK-8 is a canonical gut hormone fragment with extensive documentation in digestive physiology and appetite control. Sulfation of the tyrosine residue is important for high-affinity receptor activity.
BI 456906
Preclinical and early clinical research support meaningful metabolic effects with a tolerable safety profile. It remains investigational and is not commercially available.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.